EA202190431A1 - Гетероароматические модуляторы nmda рецептора и их применение - Google Patents

Гетероароматические модуляторы nmda рецептора и их применение

Info

Publication number
EA202190431A1
EA202190431A1 EA202190431A EA202190431A EA202190431A1 EA 202190431 A1 EA202190431 A1 EA 202190431A1 EA 202190431 A EA202190431 A EA 202190431A EA 202190431 A EA202190431 A EA 202190431A EA 202190431 A1 EA202190431 A1 EA 202190431A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heteroaromatic
application
nmda receptor
receptor modulators
methylazetidin
Prior art date
Application number
EA202190431A
Other languages
English (en)
Russian (ru)
Inventor
Роберт А. Фолькманн
Дэвид Р. Андерсон
Сэм Малекиани
Тимоти Пайзер
Грегг Ф. КИНИ
Стивен К. Лейзер
Original Assignee
Кэйдент Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэйдент Терапьютикс, Инк. filed Critical Кэйдент Терапьютикс, Инк.
Publication of EA202190431A1 publication Critical patent/EA202190431A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202190431A 2018-08-03 2019-08-02 Гетероароматические модуляторы nmda рецептора и их применение EA202190431A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
EA202190431A1 true EA202190431A1 (ru) 2021-06-11

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190431A EA202190431A1 (ru) 2018-08-03 2019-08-02 Гетероароматические модуляторы nmda рецептора и их применение

Country Status (37)

Country Link
US (5) US10584131B2 (enExample)
EP (2) EP3830092B1 (enExample)
JP (1) JP7319369B2 (enExample)
KR (1) KR102797968B1 (enExample)
CN (1) CN112513047B (enExample)
AR (1) AR115905A1 (enExample)
AU (1) AU2019368147B2 (enExample)
BR (1) BR112021001967A2 (enExample)
CA (1) CA3108519A1 (enExample)
CL (1) CL2021000294A1 (enExample)
CO (1) CO2021002898A2 (enExample)
CR (1) CR20210125A (enExample)
CU (1) CU24647B1 (enExample)
CY (1) CY1126144T1 (enExample)
DK (1) DK3830092T3 (enExample)
DO (1) DOP2021000025A (enExample)
EA (1) EA202190431A1 (enExample)
EC (1) ECSP21014902A (enExample)
ES (2) ES2951872T3 (enExample)
FI (1) FI3830092T3 (enExample)
HR (1) HRP20230774T1 (enExample)
HU (1) HUE062566T2 (enExample)
IL (1) IL280474B2 (enExample)
JO (1) JOP20210020A1 (enExample)
LT (1) LT3830092T (enExample)
MA (1) MA53351B1 (enExample)
MX (1) MX2021001367A (enExample)
PE (1) PE20210948A1 (enExample)
PH (1) PH12021550242A1 (enExample)
PL (1) PL3830092T3 (enExample)
PT (1) PT3830092T (enExample)
RS (1) RS64359B1 (enExample)
SG (1) SG11202101125VA (enExample)
SI (1) SI3830092T1 (enExample)
TW (1) TWI833783B (enExample)
WO (1) WO2020086136A2 (enExample)
ZA (1) ZA202101273B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7071917B2 (ja) * 2015-12-09 2022-05-19 カデント セラピューティクス,インコーポレーテッド ヘテロ芳香族nmda受容体モジュレーターおよびその使用
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1296958A4 (en) 2000-06-26 2004-01-28 Merck & Co Inc ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1768960A1 (en) 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
EP2066640B1 (en) 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
CN101600698B (zh) 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
WO2008076883A2 (en) 2006-12-15 2008-06-26 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
DK2160389T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
US8653059B2 (en) 2007-08-21 2014-02-18 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
WO2009146358A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
PE20120008A1 (es) 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8841289B2 (en) 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
CA2805724A1 (en) 2010-07-16 2012-01-19 Rockefeller University Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
EA029412B1 (ru) 2013-06-28 2018-03-30 Бейджин, Лтд. Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2015048503A2 (en) 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. N-arylmethyl sulfonamide negative modulators of nr2a
LT3055315T (lt) 2013-10-11 2018-10-25 F. Hoffmann-La Roche Ag Tiazolpirimidinonai kaip nmda receptorių aktyvumo moduliatoriai
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する1-置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
RU2717665C2 (ru) 2015-04-15 2020-03-24 Ф. Хоффманн-Ля Рош Аг Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
CN108601814A (zh) 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス,インコーポレーテッド ヘテロ芳香族nmda受容体モジュレーターおよびその使用
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Also Published As

Publication number Publication date
JOP20210020A1 (ar) 2021-01-25
CN112513047A (zh) 2021-03-16
MX2021001367A (es) 2021-06-23
US10584131B2 (en) 2020-03-10
JP2021534227A (ja) 2021-12-09
JP7319369B2 (ja) 2023-08-01
TWI833783B (zh) 2024-03-01
ZA202101273B (en) 2023-05-31
ES2951872T3 (es) 2023-10-25
IL280474B2 (en) 2023-09-01
SG11202101125VA (en) 2021-03-30
IL280474B1 (en) 2023-05-01
CU20210013A7 (es) 2021-09-07
PH12021550242A1 (en) 2021-11-29
DOP2021000025A (es) 2021-05-31
CR20210125A (es) 2021-06-30
CY1126144T1 (el) 2023-11-15
HUE062566T2 (hu) 2023-11-28
EP3830092B1 (en) 2023-05-03
RS64359B1 (sr) 2023-08-31
FI3830092T3 (fi) 2023-07-21
HRP20230774T1 (hr) 2023-10-27
WO2020086136A3 (en) 2020-08-06
MA53351A (fr) 2022-01-12
CU24647B1 (es) 2023-02-13
CL2021000294A1 (es) 2021-06-18
ECSP21014902A (es) 2021-05-31
DK3830092T3 (en) 2023-08-07
KR102797968B1 (ko) 2025-04-22
US20250034145A1 (en) 2025-01-30
TW202019932A (zh) 2020-06-01
AU2019368147B2 (en) 2024-05-30
US20200039987A1 (en) 2020-02-06
LT3830092T (lt) 2023-09-11
US20240199617A1 (en) 2024-06-20
US11542264B2 (en) 2023-01-03
CA3108519A1 (en) 2020-04-30
PL3830092T3 (pl) 2023-11-13
IL280474A (en) 2021-03-01
EP4223760A1 (en) 2023-08-09
US20200131190A1 (en) 2020-04-30
WO2020086136A2 (en) 2020-04-30
BR112021001967A2 (pt) 2021-04-27
ES3039982T3 (en) 2025-10-27
CN112513047B (zh) 2023-10-20
SI3830092T1 (sl) 2023-09-29
EP4223760B1 (en) 2025-06-04
AR115905A1 (es) 2021-03-10
MA53351B1 (fr) 2023-08-31
CO2021002898A2 (es) 2021-05-31
US20210403474A1 (en) 2021-12-30
PE20210948A1 (es) 2021-05-24
KR20210039432A (ko) 2021-04-09
PT3830092T (pt) 2023-07-25
US10752633B2 (en) 2020-08-25
EP3830092A2 (en) 2021-06-09
AU2019368147A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
EA202190431A1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX2019008690A (es) Compuestos espiro heterociclicos como inhibidores de magl.
MX377837B (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas.
GEP20257716B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
JOP20210330A1 (ar) مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b"
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
EA202092328A1 (ru) Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения
CL2021001547A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
EP3902539A4 (en) METHOD OF TREATMENT OF PARKINSON'S DISEASE BY ADMINISTRATION OF RESINIFERATOXIN
EA202092719A1 (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
EP4045506A4 (en) Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions
EP3752614A4 (en) OLIGONUCLEOTIDE THERAPY FOR WILSON'S DISEASE
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
EA201892724A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EA201891038A1 (ru) Антагонисты мускаринового рецептора 4 и способы их применения